Saturday, July 11, 2026

pharma · Relapsing-Remitting Multiple Sclerosis · Spinal Muscular Atrophy

Biogen

Biogen is a pharma organization headquartered in VISAKHAPATNAM, IN. Primary therapeutic focus areas include Relapsing-Remitting Multiple Sclerosis, Spinal Muscular Atrophy, systemic lupus erythematosus, IgA nephropathy,

225 Binney Street, Cambridge, MA 02142, US HQ
7,534 Employees
NMPA registrant Type
Company details
Clinical program

Dimethyl fumarate

Approved · small molecule · Multiple Sclerosis

Dimethyl fumarate for Multiple Sclerosis is a Approved program (small_molecule) at Biogen with 1 ClinicalTrials.gov record(s).

← All Biogen projects Approved small molecule completed

Internal code 109MS424

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Biogen
Phase
Approved
Modality
small_molecule
Indication
Multiple Sclerosis
Status
completed
Trials
1